Hypertension is one of the most important and prevalent major cardiovascular risk factors. It is also a risk factor for medical
problems leading to a marked increase in cardiovascular risk. Thus, appropriate and effcacious management of patients with hypertension is important. There is also an ongoing debate regarding whether major drug subgroups differ in their ability to protect against total
cardiovascular risk or etiology-specifc cardiovascular events, such as stroke and myocardial infarction. Hypertension guidelines, based
on experience from clinical trials, recognize that many individuals will require $2 antihypertensive agents at appropriate doses, either
in fxed combination or as separate prescriptions, to achieve their BP goal, particularly in patients at high cardiovascular risk. If possible,
initiation of fxed-dose combinations should be chosen, because of the advantages for compliance to treatment. In this context, we aimed
to review fxed-dose combinations of irbesartan/hydrochlorothiazide in the management of hypertension.